3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
12
Terminated
5
Withdrawn
1
Recruiting
1
Available
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Leukemia, Biphenotypic, Acute
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, T-Cell
2
Burkitt Lymphoma
2
Rhabdoid Tumor
1
Recurrence
1
Pyloric Stenosis, Hypertrophic
1
Prostatic Neoplasms
1
Prostate Cancer Metastatic
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Pinealoma
1
Pancreatitis
1
Pancreatic Intraductal Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Medulloblastoma
1
Lymphoma, B-Cell
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myeloid, Acute
1
Hodgkin Disease
1
Hematopoietic and Lymphatic System Neoplasm
1
Hematologic Neoplasms
1
Fistula
1
Duodenal Neoplasms
1
Down Syndrome
1
Blastic Plasmacytoid Dendritic Cell Neoplasm
1
Interventions
Magnetic Resonance Spectroscopy
51
Specimen Handling
42
enzalutamide
35
Androgen Antagonists
34
Radiosurgery
32
Radiotherapy
31
Prednisone
26
darolutamide
24
Abiraterone Acetate
24
Leuprolide
22
Docetaxel
22
apalutamide
20
Pluvicto
19
abiraterone
18
Standard of Care
18
Triptorelin Pamoate
17
Radiation
17
Biopsy
16
relugolix
15
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
15
Goserelin
14
Blood Specimen Collection
13
gallium 68 PSMA-11
12
pembrolizumab
11
X-Rays
11
Surveys and Questionnaires
11
luprolide acetate gel depot
10
Carboplatin
10
Methods
9
Interviews as Topic
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Prostatic Neoplasms
×
Hydrocortisone
×
Clear all
NCT06136650
2026-05-27
MK-5684-004
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,314 enrolled